LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "resectable stage" as a keyword



Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)

Sign Up to like & get
recommendations! Published in 2019 at "British Journal of Cancer"

DOI: 10.1038/s41416-019-0447-0

Abstract: BackgroundNeoadjuvant chemotherapy (CT) followed by radiotherapy (RT) and surgery showed a median survival of 28.7 months in resectable stage IIIB non-small-cell lung cancer (NSCLC) patients (pts). Here, we evaluate the impact of concomitant cetuximab to… read more here.

Keywords: trial; stage iiib; concomitant cetuximab; resectable stage ... See more keywords

Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial.

Sign Up to like & get
recommendations! Published in 2021 at "Nature medicine"

DOI: 10.1038/s41591-021-01510-7

Abstract: Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-based intralesional oncolytic immunotherapy approved for the treatment of unresectable melanoma. The present, ongoing study aimed to estimate the treatment effect of neoadjuvant T-VEC on recurrence-free… read more here.

Keywords: melanoma; surgery; stage iiib; resectable stage ... See more keywords

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).

Sign Up to like & get
recommendations! Published in 2024 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2024.42.16_suppl.9578

Abstract: 9578 Background: Several studies have shown the efficacy of neoadjuvant treatment (NT) with immune checkpoint inhibitors (ICI) for resectable stage III/IV melanoma. However, real-life data are lacking. Methods: NEOMEL is a national multicenter retrospective study… read more here.

Keywords: stage iii; iii melanoma; resectable stage; stage ... See more keywords

Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial.

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2025.43.16_suppl.9512

Abstract: 9512 Background: The CAP 03 study demonstrated significant efficacy for camrelizumab combined with apatinib and temozolomide as first-line therapy for advanced acral melanoma (AM), achieving a 64.0% objective response rate and a median progression-free survival… read more here.

Keywords: stage iii; cap neo; resectable stage; stage ... See more keywords

Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC

Sign Up to like & get
recommendations! Published in 2023 at "Frontiers in Oncology"

DOI: 10.3389/fonc.2023.1083417

Abstract: Background To date, identifying resectable stage I non-small cell lung cancer (NSCLC) patients likely to benefit from adjuvant therapy (ADT) remains a major challenge. Previous studies suggest that circulating tumor DNA (ctDNA) is emerging as… read more here.

Keywords: resectable stage; ctdna; group; detection ... See more keywords